Quality of life among Children on Dialysis and Omega 3 Fatty Acid Supplementation

Quality of life among Children on Dialysis and effect of Omega 3 Fatty Acid Supplementation

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202001481782473

Enrollment

Registered

2020-01-22

Start date

2019-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine Paediatrics Kidney Disease

Interventions

Omega 3 Fatty Acid Supplementation

Omega 3 Fatty Acid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children with ESRD with - A glomerular filtration rate of less than 10 ml/min/1.73 m2 - Age less than 14 years, and - Regular hemodialysis at least three sessions per week for at least 3 months before the study will be included in the study.

Exclusion criteria

Exclusion criteria: Patients with - Pre-dialysis stages of CKD, - On chronic peritoneal dialysis, - Regular hemodialysis < 3 months, - Primary (non-uremic) cardiovascular disease will be excluded from the study. Forty nine patients were enrolled, 31 patients (17 males and 14 females, aged from 8-14 years) fit the inclusion criteria while 18 patients were excluded (due to exclusion criteria, acute infection, hospitalization, febrile illness and non-compliance).

Design outcomes

Primary

Measure	Time frame
Study the effect of ?-3 FA administration on quality of life domains among studied patient group	—

Secondary

Measure	Time frame
Inflammatory Markers	—

Countries

Egypt

Contacts

Public ContactZeinab Kasemy

Assistant professor at Public health department

zeinbkasemy@yahoo.com+201068787807

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026